AMLX · CIK 0001658551 · FY2025 live · 2025-12-31
Amylyx Pharmaceuticals, Inc.
View as
Model
Classic Z
FY2025
3.09
Zone
Safe
Prior
—
Market DD
—
1y PD
—
3.09
Z″ 7.18
Score 3.09 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.901.2 × = 1.09X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−2.261.4 × = −3.16X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.463.3 × = −1.52X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
11.150.6 × = 6.69X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.001 × = 0.00
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings.
Meridian Rank
61.36
0–100 · Classic Z family
Book standing
81
Year change
—
Market PD
—
O-score
9
Events on this name
Same published rows as Today.
Approaching grey
watch · 41
- Live score: — → 3.09
- Cut: — → 1.80
Overview
rule-v1
Amylyx Pharmaceuticals, Inc. is on classic Z at 3.09 (safe) for FY2025, from an SEC 10-K. Book equity / liabilities is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers. Buybacks can send retained earnings negative at otherwise healthy issuers. X4 is book equity.
Book screen Safe; market PD —. Market PD has not been priced on this name.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 84th percentile in Healthcare.
Filing line items
Current assets
$324M
Total assets
$333M
Current liabilities
$23M
Total liabilities
$27M
Working capital
$301M
Retained earnings
−$751M
EBIT
−$153M
Total sales
$0
Book equity
$305M
Accession 0001193125-26-086645. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as is a display overlay. X4 is book equity. Pulled 13 Sept 2026.